Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1066

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure

Interventions

DRUG: Finerenone (BAY94-8862)
DRUG: Placebo
DRUG: Inspra (eplerenone)

Sponsor

Bayer